These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11697485)

  • 1. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
    Takagi T; Saotome T
    Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
    Saotome T; Takagi T; Sakai C; Kumagai K; Tamaru J
    Ann Oncol; 2000 Jan; 11(1):115-6. PubMed ID: 10690400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
    Tobinai K; Hotta T; Saito H; Ohnishi K; Ohno R; Ogura M; Ariyoshi Y; Takeyama K; Kobayashi T; Ohashi Y; Shirakawa S
    Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
    Ohtsu T; Sasaki Y; Igarashi T; Murayama T; Kobayashi Y; Tobinai K
    Jpn J Clin Oncol; 1998 Aug; 28(8):502-6. PubMed ID: 9769785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
    Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
    Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
    Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
    Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
    Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.
    Niitsu N; Iijima K; Chizuka A
    Ann Hematol; 2001 Jul; 80(7):411-6. PubMed ID: 11529467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPT-11. The European experience.
    Armand JP; Terret C; Couteau C; Rixe O
    Ann N Y Acad Sci; 1996 Dec; 803():282-91. PubMed ID: 8993522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
    Ohno R; Yoshida Y; Oguro M; Ogawa M; Sakai Y; Furue H; Ariyoshi Y; Saito H; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):75-82. PubMed ID: 8291918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
    Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
    Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
    Ohno R; Okada K; Masaoka T; Kuramoto A; Arima T; Yoshida Y; Ariyoshi H; Ichimaru M; Sakai Y; Oguro M
    J Clin Oncol; 1990 Nov; 8(11):1907-12. PubMed ID: 2230878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
    Urushihata K; Koizumi T; Kaneki T; Yamaguchi S; Fujimoto K; Kubo K
    Intern Med; 2002 Aug; 41(8):648-50. PubMed ID: 12211535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.